Technical Analysis for AOLS - Aeolus Pharmaceuticl

Grade Last Price % Change Price Change
D 0.006 -3.23% -0.0002
AOLS closed down 3.23 percent on Friday, May 7, 2021, on 1.37 times normal volume.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Down Down
Historical AOLS trend table...

Date Alert Name Type % Chg
20 DMA Resistance Bearish 0.00%
180 Bearish Setup Bearish Swing Setup 0.00%
Bollinger Band Squeeze Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Bollinger Band Squeeze Range Contraction -3.23%
Narrow Range Bar Range Contraction -3.23%
Wide Bands Range Expansion -3.23%
Gapped Down Weakness -3.23%
20 DMA Resistance Bearish -6.25%
Older End-of-Day Signals for AOLS ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% 5 days ago
Up 2% 5 days ago
Up 1% 5 days ago
20 DMA Resistance 5 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Aeolus Pharmaceuticl Description

Aeolus Pharmaceuticals, Inc. is a biopharmaceutical company. The Company focuses on developing a platform of compounds for use in biodefense, fibrosis, oncology, infectious disease and diseases of the central nervous system. As of September 30, 2016, the Company's platform consisted of approximately 180 compounds licensed from the University of Colorado (UC), Duke University (Duke) and National Jewish Health (NJH). The Company's lead compound is AEOL 10150, which is being developed as a medical countermeasure (MCM) against the pulmonary sub-syndrome of acute radiation syndrome (Pulmonary Acute Radiation Syndrome or Lung-ARS) and the delayed effects of acute radiation exposure (DEARE). Its other product is AEOL 11114 and AEOL 20415. AEOL 10150 is indicated for the treatment of radiation oncology and idiopathic pulmonary fibrosis. AEOL 11114 is indicated for the treatment of Parkinson's disease and epilepsy. AEOL 20415 is an orally-available, anti-infective compound.


Classification

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic
Keywords: Medicine Health Biopharmaceutical Diseases Radiation Parkinson's Disease Fibrosis Radiation Therapy Epilepsy Treatment Of Parkinson's Disease Infectious Disease Pulmonary Fibrosis Idiopathic Pulmonary Fibrosis Duke University

Is AOLS a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.02
52 Week Low 0.0008
Average Volume 290,295
200-Day Moving Average 0.0041
50-Day Moving Average 0.0078
20-Day Moving Average 0.0063
10-Day Moving Average 0.0061
Average True Range 0.0012
ADX 16.15
+DI 30.1676
-DI 20.6704
Chandelier Exit (Long, 3 ATRs ) 0.0044
Chandelier Exit (Short, 3 ATRs ) 0.0086
Upper Bollinger Band 0.0075
Lower Bollinger Band 0.0051
Percent B (%b) 0.38
BandWidth 38.0952
MACD Line -0.0006
MACD Signal Line -0.0004
MACD Histogram -0.0001
Fundamentals Value
Market Cap 912.52 Thousand
Num Shares 152 Million
EPS -0.03
Price-to-Earnings (P/E) Ratio -0.20
Price-to-Sales 0.22
Price-to-Book 0.81
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0066
Resistance 3 (R3) 0.0067 0.0065 0.0065
Resistance 2 (R2) 0.0065 0.0064 0.0065 0.0065
Resistance 1 (R1) 0.0063 0.0063 0.0062 0.0062 0.0064
Pivot Point 0.0061 0.0061 0.0061 0.0061 0.0061
Support 1 (S1) 0.0059 0.0060 0.0058 0.0058 0.0056
Support 2 (S2) 0.0057 0.0059 0.0057 0.0055
Support 3 (S3) 0.0055 0.0057 0.0055
Support 4 (S4) 0.0054